Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases. The MCRB average annual return since 2015 is shown above.
The Average Annual Return on the MCRB average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MCRB average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MCRB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|